Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Share-based Compensation (2017 - 2025)

Cue Biopharma (CUE) has disclosed Share-based Compensation for 9 consecutive years, with $610000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 60.95% to $610000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2025, down 30.7% year-over-year, with the annual reading at $4.7 million for FY2025, 30.7% down from the prior year.
  • Share-based Compensation hit $610000.0 in Q4 2025 for Cue Biopharma, down from $1.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.3 million in Q3 2021 to a low of $610000.0 in Q4 2025.
  • Historically, Share-based Compensation has averaged $2.0 million across 5 years, with a median of $2.1 million in 2022.
  • Biggest five-year swings in Share-based Compensation: surged 30.36% in 2021 and later tumbled 60.95% in 2025.
  • Year by year, Share-based Compensation stood at $3.0 million in 2021, then decreased by 29.0% to $2.1 million in 2022, then decreased by 1.89% to $2.1 million in 2023, then dropped by 24.61% to $1.6 million in 2024, then tumbled by 60.95% to $610000.0 in 2025.
  • Business Quant data shows Share-based Compensation for CUE at $610000.0 in Q4 2025, $1.5 million in Q3 2025, and $1.3 million in Q2 2025.